XBIT
XBiotech Inc.
$2.40
-$0.15(-5.88%)
50
Overall
60
Value
58
Tech
34
Quality
Market Cap
$74.09M
Volume
51.14K
52W Range
$2.09 - $7.00
Target Price
$18.00
Company Overview
| Mkt Cap | $74.09M | Price | $2.40 |
| Volume | 51.14K | Change | -5.88% |
| P/E Ratio | -1.9 | Open | $2.51 |
| Revenue | -- | Prev Close | $2.55 |
| Net Income | $-38.5M | 52W Range | $2.09 - $7.00 |
| Div Yield | N/A | Target | $18.00 |
| Overall | 50 | Value | 60 |
| Quality | 34 | Technical | 58 |
No chart data available
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest News
XBiotech CEO John Simard Announces Retirement
TipRanks Auto-Generated Newsdesk•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XBIT | $2.40 | -5.9% | 51.14K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |